← Back to Clinical Trials
Recruiting NCT07087145

NCT07087145 Feasibility of HPV Testing With Mail-delivered Sample Collection Kits

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07087145
Status Recruiting
Phase
Sponsor University of California, San Francisco
Condition HPV Infection
Study Type OBSERVATIONAL
Enrollment 135 participants
Start Date 2024-11-17
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 35 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Mail-based Saliva Sample KitStudy-related Surveys

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 135 participants in total. It began in 2024-11-17 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

People living with human immunodeficiency virus (PLWH) have an estimated 1.6-6.0 times increased risk of developing oropharyngeal cancer (OPC) compared with individuals in the general population. 70% of OPCs are caused by human papillomavirus (HPV), and PLWH also have an increased prevalence of oral HPV infection. Disparities by race/ethnicity also include a later stage of diagnosis and less frequent cancer-directed treatment for members of ethnic minority groups. There is little known regarding the racial/ethnic differences in oral HPV infection, persistence of oral HPV infection, or progression of oral HPV infection to OPC among PLWH. This is an observational, prospective cohort study to investigate the feasibility of alternative sample collection methods for HPV testing among PLWH.

Eligibility Criteria

Inclusion Criteria: 1. Over 35 years of age 2. Member of a sexual or gender group considered sexual minority men (men who have sex with men, trans-women) 3. Person living with HIV 4. Willing and able to receive a package through United States (US) postal service 5. Willing and able to return a package through FedEx 6. Able to attend a clinic visit at University of California, San Francisco (UCSF) Mt. Zion campus Exclusion Criteria: * Does not meet the above criteria

Contact & Investigator

Central Contact

William Juarez

✉ William.Juarez@ucsf.edu

📞 415-949-8336

Principal Investigator

Alexandra Hernandez Levenston, MD, MPH

PRINCIPAL INVESTIGATOR

University of California, San Francisco

Frequently Asked Questions

Who can join the NCT07087145 clinical trial?

This trial is open to participants of all sexes, aged 35 Years or older, studying HPV Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07087145 currently recruiting?

Yes, NCT07087145 is actively recruiting participants. Contact the research team at William.Juarez@ucsf.edu for enrollment information.

Where is the NCT07087145 trial being conducted?

This trial is being conducted at San Francisco, United States.

Who is sponsoring the NCT07087145 clinical trial?

NCT07087145 is sponsored by University of California, San Francisco. The principal investigator is Alexandra Hernandez Levenston, MD, MPH at University of California, San Francisco. The trial plans to enroll 135 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology